Laboratory Analytical Instruments
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Discounted Cash Flow Valuation of Cytek Biosciences, Inc.
Growth
%
%
Discount
%
%
Multiple
g\r | +10% | +11% | +12% | +13% | +14% |
---|---|---|---|---|---|
0% | 10 | 9 | 8 | 8 | 7 |
+1% | 11 | 10 | 9 | 8 | 8 |
+2% | 13 | 11 | 10 | 9 | 8 |
+3% | 14 | 13 | 11 | 10 | 9 |
+4% | 17 | 14 | 12 | 11 | 10 |
Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF | $1.67M | $1.01M | $610.5K | $369.1K | $223.2K | $134.9K | $81.59K | $49.33K | $29.83K | $18.04K | $10.9K | $109K |
DCF | $878K | $461.6K | $242.7K | $127.6K | $67.09K | $35.28K | $18.55K | $9.751K | $5.127K | $2.696K | $26.96K | |
Value | $1.875M |
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|
Net Margin | 3.5% | 0% | 1.5% | -6.3% | -5.7% |
ROA | 6.6% | 2% | 0.24% | -3.2% | -3.2% |
ROE | -20% | 0% | 0.58% | -3.1% | -2.9% |
The average Net Margin over the past 5 years is -2.39%.
The trend of Net Margin over the past 5 years is -7.81%.
The average ROA over the past 5 years is -1.47%.
The trend of ROA over the past 5 years is -3.42%.
The average ROE over the past 5 years is -1.25%.
The trend of ROE over the past 5 years is -3.67%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM | |||||
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | - | 0.00 | -0.10 | 2.60 | 0.88 | |||||
Debt Equity | - | 0.00 | 0.01 | 0.00 | 0.00 | |||||
MIN | ||||||||||
Graham Stability | - | - | - | -640% | -640% |
The Debt/FCF trailing twelve month is 0.88.
The trend of Debt/FCF over the past 5 years is 2.71.
Graham’s Stability measure stands at -6.39.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2020 | 12-2022 | Trend |
---|---|---|---|
Revenue | 28% | 18% | -10% |
Net Income | - | - | - |
Stockholders Equity | - | -7.6% | -13% |
FCF | -64% | - | - |
The Revenue CAGR over the past 5 years is -.
The trend of Revenue growth rate over the past 5 years is -10.08%.
The Earnings CAGR over the past 5 years is -.
The trend of Earnings growth rate over the past 5 years is -.
The Equity CAGR over the past 5 years is -.
The trend of Equity growth rate over the past 5 years is -12.61%.
The FCF CAGR over the past 5 years is -.
The trend of FCF growth rate over the past 5 years is -.